Compass Pathways Plc ADR
Fechado
12.51 4.95
Visão Geral
Variação de preço das ações
24h
Mín
12.31
Máximo
12.54
Rendimento | 185M 91M |
|---|---|
EPS | -0.3 |
Funcionários | 156 |
EBITDA | 139M 93M |
Recomendações | Compra Forte |
|---|---|
Previsão para 12 meses | +87.55% upside |
Próximos Ganhos | 30 de jul. de 2026 |
|---|
Capitalização de Mercado | 230M 1.5B |
|---|---|
Abertura anterior | 7.56 |
Fecho anterior | 12.51 |
Compass Pathways Plc ADR Gráfico
O desempenho passado não é um indicador confiável de resultados futuros.
Sobre Compass Pathways Plc ADR
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
